Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2009

01.10.2009

Pharmaceutical care for patients with ischemic stroke: improving the patients quality of life

verfasst von: Carina Hohmann, Jürgen M. Klotz, Roland Radziwill, Andreas H. Jacobs, Thomas Kissel

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives To improve patients health-related quality of life (HQL) after transient ischemic attack (TIA) or ischemic stroke; to guarantee an effective secondary prevention; to increase the patient’s satisfaction with recommendations regarding their medication by pharmacists. Setting Stroke Unit, neurological ward at the Klinikum Fulda, rehabilitation hospitals and community-based pharmacies in the region of Fulda, Germany. Method Patients with TIA or ischemic stroke were included. The patients were assigned to an intervention group (IG) or a control group (CG). The individual assignment of patients to IG or CG was based on the type of the local pharmacy to which patients belong. Community-based pharmacies either delivered standard care (CG) or provided additional intensified pharmaceutical care (PC; IG). Pharmacies delivering PC belong to a pre-existing “Quality Assurance Working Group” (QAWG). To evaluate the patient’s HQL, the Short Form-36 (SF-36) was used at study entry in hospital and at 12 months. The secondary prevention was documented at study entry in hospital and at 12 months. The patients’ satisfaction was measured by a questionnaire at the end of the study. Main outcome measures Patients’ HQL; secondary prevention; patients’ satisfaction with recommendations of the pharmacists with regards to their medication. Results Out of 1316 patients screened for participation in this study, 255 were recruited with 90/255 patients assigned to the IG and 165/255 patients assigned to the CG. During the study, the HQL of the patients in the IG did not change significantly. A significant decrease in the HQL was observed for the CG in 7/8 subscales and in both summary measures of the SF-36. After 12 months, 85.3% of the patients in the IG and 86.3% of the patients in the CG were treated with antiplatelet drugs or oral anticoagulants in accordance to treatment guidelines. Patients in the IG were significantly more satisfied with the individualized recommendations of the pharmacists than patients in the CG. Conclusion Our findings indicate that an intensified PC of patients after ischemic stroke by dedicated pharmacists may have a positive impact on HQL and patients’ satisfaction. PC in this study had no impact on adherence to secondary prevention medication.
Literatur
1.
Zurück zum Zitat Kolominsky-Rabas P, Sarti C, Heuschmann P, Graf C, Siemonsen S, Neudoerfer B, et al. A prospective community-based study of stroke in Germany—the Erlangen stroke project (ESPro)—incidence and case fatality at 1, 3 and 12 months. Stroke. 1998;29(12):2501–6.CrossRefPubMed Kolominsky-Rabas P, Sarti C, Heuschmann P, Graf C, Siemonsen S, Neudoerfer B, et al. A prospective community-based study of stroke in Germany—the Erlangen stroke project (ESPro)—incidence and case fatality at 1, 3 and 12 months. Stroke. 1998;29(12):2501–6.CrossRefPubMed
2.
Zurück zum Zitat Manolio TA, Kronmal RA, Burke GL, O’Leary DH, Price TH. Short-term predictors of incident stroke in older adults: the Cardiovascular Health study. Stroke. 1996;27(9):1479–86.CrossRefPubMed Manolio TA, Kronmal RA, Burke GL, O’Leary DH, Price TH. Short-term predictors of incident stroke in older adults: the Cardiovascular Health study. Stroke. 1996;27(9):1479–86.CrossRefPubMed
3.
Zurück zum Zitat Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome and treatment in subtypes of ischemic stroke: the German Stroke Data Bank. Stroke. 2001;32(11):2559–66.CrossRefPubMed Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome and treatment in subtypes of ischemic stroke: the German Stroke Data Bank. Stroke. 2001;32(11):2559–66.CrossRefPubMed
4.
Zurück zum Zitat Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998;114(5):683S–98S.CrossRefPubMed Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998;114(5):683S–98S.CrossRefPubMed
5.
Zurück zum Zitat Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71–86.CrossRef Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71–86.CrossRef
6.
Zurück zum Zitat Deutsche Gesellschaft für Neurologie: www.dgn.org: Primär- und Sekundärprävention der zerebralen Ischämie [German Neurological Society: www.dgn.org: Primary and secondary prevention of cerebral ischemia] (updated January 2006). Accessed 10 July 2008. Deutsche Gesellschaft für Neurologie: www.​dgn.​org: Primär- und Sekundärprävention der zerebralen Ischämie [German Neurological Society: www.​dgn.​org: Primary and secondary prevention of cerebral ischemia] (updated January 2006). Accessed 10 July 2008.
7.
Zurück zum Zitat MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–74.CrossRefPubMed MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–74.CrossRefPubMed
8.
Zurück zum Zitat Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke—an overview of published reviews. Stroke. 2004;35(3):776–85.CrossRefPubMed Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke—an overview of published reviews. Stroke. 2004;35(3):776–85.CrossRefPubMed
9.
Zurück zum Zitat Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMed Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMed
10.
Zurück zum Zitat Schulz M, Morck H, Braun R. Neues Apothekenprofil: good pharmacy practice und pharmaceutical care [New pharmacy profile: good pharmacy practice and pharmaceutical care]. Pharm Ztg. 1993;138:3191–7. Schulz M, Morck H, Braun R. Neues Apothekenprofil: good pharmacy practice und pharmaceutical care [New pharmacy profile: good pharmacy practice and pharmaceutical care]. Pharm Ztg. 1993;138:3191–7.
11.
Zurück zum Zitat Eickhoff C, Schulz M. Pharmaceutical care in community pharmacies: practice and research in Germany. Ann Pharmacother. 2006;40(4):729–35.CrossRefPubMed Eickhoff C, Schulz M. Pharmaceutical care in community pharmacies: practice and research in Germany. Ann Pharmacother. 2006;40(4):729–35.CrossRefPubMed
12.
Zurück zum Zitat Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61–5.PubMed Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61–5.PubMed
13.
Zurück zum Zitat Anderson C, Laubscher S, Burns R. Validation of the Short Form 36 (SF-36) Health Survey questionnaire among stroke patients. Stroke. 1996;27(10):1812–6.CrossRefPubMed Anderson C, Laubscher S, Burns R. Validation of the Short Form 36 (SF-36) Health Survey questionnaire among stroke patients. Stroke. 1996;27(10):1812–6.CrossRefPubMed
14.
Zurück zum Zitat Hobart JC, Williams LS, Moran K, Thompson AJ. Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke. 2002;33(5):1348–56.CrossRefPubMed Hobart JC, Williams LS, Moran K, Thompson AJ. Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke. 2002;33(5):1348–56.CrossRefPubMed
15.
Zurück zum Zitat Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835–40.CrossRefPubMed Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835–40.CrossRefPubMed
16.
Zurück zum Zitat German Neurological Society and the German Stroke Society: www.dgn.org: Primary and secondary prevention of cerebral ischaemia (updated September 2005). Accessed 10 July 2008. German Neurological Society and the German Stroke Society: www.​dgn.​org: Primary and secondary prevention of cerebral ischaemia (updated September 2005). Accessed 10 July 2008.
17.
Zurück zum Zitat Gourley GK, Gourley DR, La Monica Rigolosi E, Reed P, Solomon DK, Washington E. Development and validation of the pharmaceutical care satisfaction questionnaire. Am J Manag Care. 2001;7(5):461–6.PubMed Gourley GK, Gourley DR, La Monica Rigolosi E, Reed P, Solomon DK, Washington E. Development and validation of the pharmaceutical care satisfaction questionnaire. Am J Manag Care. 2001;7(5):461–6.PubMed
18.
Zurück zum Zitat Winterstein A. Pharmaceutical care—Grundlagen und Methoden zur Nutzenevaluation dargestellt am Beispiel einer experimentellen Studie zur pharmazeutischen Betreuung älterer multimorbider Patienten [Pharmaceutical care—basics and methods for evaluating benefits illustrated in an experimental study on the pharmaceutical care of elderly patients]. Berlin: Humboldt-Universität; 1999. Winterstein A. Pharmaceutical care—Grundlagen und Methoden zur Nutzenevaluation dargestellt am Beispiel einer experimentellen Studie zur pharmazeutischen Betreuung älterer multimorbider Patienten [Pharmaceutical care—basics and methods for evaluating benefits illustrated in an experimental study on the pharmaceutical care of elderly patients]. Berlin: Humboldt-Universität; 1999.
19.
Zurück zum Zitat Schulz M, Verheyen F, Mühlig S, Müller JM, Mühlbauer K, Knop-Schneickert E, et al. Pharmaceutical Care Services for asthma patients: a controlled intervention study. J Clin Pharmacol. 2001;41(6):668–76.CrossRefPubMed Schulz M, Verheyen F, Mühlig S, Müller JM, Mühlbauer K, Knop-Schneickert E, et al. Pharmaceutical Care Services for asthma patients: a controlled intervention study. J Clin Pharmacol. 2001;41(6):668–76.CrossRefPubMed
20.
Zurück zum Zitat Mangiapane S, Schulz M, Muhlig S, Ihle P, Schubert I, Waldmann H. Community pharmacy-based pharmaceutical care for asthma patients. Ann Pharmacother. 2005;39(11):1817–22.CrossRefPubMed Mangiapane S, Schulz M, Muhlig S, Ihle P, Schubert I, Waldmann H. Community pharmacy-based pharmaceutical care for asthma patients. Ann Pharmacother. 2005;39(11):1817–22.CrossRefPubMed
21.
Zurück zum Zitat Graesel E, Biehler J, Schmidt R, Schupp W. Intensification of the transition between inpatient neurological rehabilitation and home care of stroke patients. Controlled clinical trial with follow-up assessment six months after discharge. Clin Rehabil. 2005;19(7):725–36.CrossRef Graesel E, Biehler J, Schmidt R, Schupp W. Intensification of the transition between inpatient neurological rehabilitation and home care of stroke patients. Controlled clinical trial with follow-up assessment six months after discharge. Clin Rehabil. 2005;19(7):725–36.CrossRef
22.
Zurück zum Zitat Volume CI, Farris KB, Kassam R, Cox CE, Cave A. Pharmaceutical care research and education project: patient outcomes. J Am Pharm Assoc. 2001;41(3):411–20. Volume CI, Farris KB, Kassam R, Cox CE, Cave A. Pharmaceutical care research and education project: patient outcomes. J Am Pharm Assoc. 2001;41(3):411–20.
23.
Zurück zum Zitat Petty DR, Zermansky AG, Raynor DK, Vail A, Lowe CJ, Freemantle N, et al. “No thank you”: why elderly patients declined to participate in a research study. Pharm World Sci. 2001;23(1):22–7.CrossRefPubMed Petty DR, Zermansky AG, Raynor DK, Vail A, Lowe CJ, Freemantle N, et al. “No thank you”: why elderly patients declined to participate in a research study. Pharm World Sci. 2001;23(1):22–7.CrossRefPubMed
Metadaten
Titel
Pharmaceutical care for patients with ischemic stroke: improving the patients quality of life
verfasst von
Carina Hohmann
Jürgen M. Klotz
Roland Radziwill
Andreas H. Jacobs
Thomas Kissel
Publikationsdatum
01.10.2009
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2009
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-009-9315-y

Weitere Artikel der Ausgabe 5/2009

International Journal of Clinical Pharmacy 5/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.